Corbus Pharmaceuticals updates investor presentation; no new financial or clinical data disclosed

Corbus Pharmaceuticals Holdings, Inc.

Exhibit 99.1 is an updated corporate deck titled 'Connecting Innovation to Purpose,' dated October 15, 2026.
The filing text discloses no financial results, trial data, guidance or deal terms, and no substantive content from the deck was included.
Signed by CEO Yuval Cohen; Corbus (CRBP) common stock is listed on the Nasdaq Capital Market.
Company headquarters listed as 500 River Ridge Drive, Norwood, Massachusetts.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.